title: Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination.
abstract: Compared to whole cell pertussis (wcP) vaccines, acellular pertussis vaccines (aP) have a better safety profile with lower reactogenicity, although their short and long-term efficacy was found to be slightly lower. Up to now, no established serological parameter to predict long-term protection exists. IgG-anti-pertussis avidity possibly determines the effect of different pertussis vaccines and boosting intervals on long-term immunity. Thus, the avidity of a tetanus-diphtheria-aP booster at 10-14 years was tested in three groups of adolescents who had been previously immunized with either five doses of aP (5aP) at 2, 4, 6, 15-18 months and 5-6 years of age, four doses of aP (4aP) or four doses of wcP (4wcP) at 2, 4, 6 and 15-18 months of age. Relative avidity index (RAI) of IgG-anti-pertussis toxin (PT) and IgG-anti-filamentous-hemagglutinin (FHA) was assessed by an adapted ELISA. RAI of IgG-anti-PT and of IgG-anti-FHA correlated positively with antibody concentrations in the pre-vaccination and in the post-vaccination analysis and significantly increased after adolescent booster with aP in all groups. Pre- and post-vaccination, the proportion of participants with IgG-anti-PT RAI>40% (moderate to high avidity) was significantly lower in the 4wcP group (52.9% and 88.9%) compared to the 5aP group (89.5% and 100.0%). In conclusion, TdaP in adolescence induces an increase of antibody avidity and, thus, is able to enhance the binding-quality of antibodies against pertussis. The study suggests including antibody avidity into serological studies on the humoral response to provide information about the long-term efficacy of the vaccine.
authors.affiliation: Department of Pediatrics, University of Wuerzburg, Wuerzburg, Germany. Prelog_M@kinderklinik.uni-wuerzburg.de
authors.forename: M
authors.initials: M
authors.lastname: Prelog
authors.forename: G
authors.initials: G
authors.lastname: Almanzar
authors.forename: N
authors.initials: N
authors.lastname: Rieber
authors.forename: B
authors.initials: B
authors.lastname: Ottensmeier
authors.forename: M
authors.initials: M
authors.lastname: Zlamy
authors.forename: J
authors.initials: J
authors.lastname: Liese
mesh_terms: D018829:Adhesins, Bacterial / Q000276:immunology; D000293:Adolescent; D000907:Antibodies, Bacterial / Q000276:immunology*; D000915:Antibody Affinity / Q000276:immunology; D001886:Bordetella pertussis / Q000276:immunology; D002648:Child; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology*; D008297:Male; D037342:Pertussis Toxin / Q000276:immunology; D010567:Pertussis Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D014611:Vaccination / Q000379:methods; D010566:Virulence Factors, Bordetella / Q000276:immunology
chemical_list: D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D007074:Immunoglobulin G; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella; C065273:filamentous hemagglutinin adhesin, Bordetella pertussis; D037342:Pertussis Toxin